Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422284 | 0.82 | EPAS1 (0.36) | EPAS1MAPTLMNACYP2C9GAA | |
| SCHEMBL17241303 | 0.81 | ALDH1A1 (0.36) | LMNAALDH1A1HPGDRAB9AHTT | |
| SCHEMBL3649084 | 0.81 | MAPT (0.40) | MAPTLMNACYP2C9KDM4EALDH1A1 | |
| SCHEMBL423730 | 0.80 | SQOR (0.38) | EPAS1MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL19068775 | 0.79 | GAA (0.41) | MAPTLMNACYP2C9KDM4EALDH1A1 | |
| SCHEMBL17929423 | 0.78 | PIM1 (0.39) | MAPTLMNACYP2C9KDM4EALDH1A1 | |
| SCHEMBL21563533 | 0.78 | ALDH1A1 (0.44) | MAPTLMNACYP2C9KDM4EALDH1A1 | |
| SCHEMBL27807167 | 0.78 | NPC1 (0.39) | MAPTLMNACYP2C9KDM4EALDH1A1 | |
| SCHEMBL17993346 | 0.76 | TUBB1 (0.37) | LMNARAB9AHTTMAPK1 | |
| SCHEMBL420481 | 0.75 | EPAS1 (0.34) | EPAS1MAPTKDM4EALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112351-B1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-9914707-B2 | Naphthylamide compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-03-13 | — | — | US | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170066723-A1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3112351-A1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015171527-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015171527-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| EP-2246333-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| EP-1638941-B1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LAB (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-7598283-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| US-7297709-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABBOTT LABORATORIES | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | EPAS1 2273/4885MAPT 1484/4885LMNA 3448/4885 |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | EPAS1 2563/4885MAPT 44/4885LMNA 3428/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | EPAS1 2273/4885MAPT 1484/4885LMNA 3448/4885 |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABL1, MAP3K19, MAP3K1 | EPAS1 1628/4885MAPT 3170/4885LMNA 3486/4885 |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | EPAS1 2273/4885MAPT 1484/4885LMNA 3448/4885 |
| US-20170066723-A1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | KDR, FLT1, FLT4 | EPAS1 312/4885MAPT 1181/4885LMNA 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.